ROSIGLITAZONE THRPY FOR PREV OF COR ARTERY DISEASE IN PTS W/IMPAIRD GLUCOSE TOL

罗格列酮苏吡酮用于预防葡萄糖耐受不良患者的冠状动脉疾病

• 批准号: 7604394
• 负责人: JANE E REUSCH
• 金额: $ 0.84万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604394
• 关键词: Arteries; Computer Retrieval of Information on Scientific Projects Database; Coronary Arteriosclerosis; Disease; Disease Progression; Funding; Glucose; Grant; Institution; Placebos; Prevention; Research; Research Personnel; Resources; Source; United States National Institutes of Health; impaired glucose tolerance; rosiglitazone

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an 18-month study looking at prevention of coronary artery disease progression in people with impaired glucose tolerance on rosiglitazone vs. placebo.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项为期18个月的研究，旨在观察服用罗格列酮和安慰剂的糖耐量受损人群预防冠状动脉疾病进展的情况。